Estrogen Receptor and Receptor Tyrosine Kinase Signaling: Use of Combinatorial Hormone and Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2-Targeted Therapies for Breast Cancer

被引:10
作者
Zabransky, Daniel J. [1 ]
Park, Ben Ho [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA
关键词
PHOSPHATIDYLINOSITOL; 3-KINASE; PIK3CA GENE; MCF-7; CELLS; BIOLOGY; ACTIVATION; RESISTANCE; MUTATIONS; PATHWAYS; ERBB2; AKT;
D O I
10.1200/JCO.2013.53.5070
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:1084 / 1086
页数:3
相关论文
共 24 条
[1]   Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance [J].
Arpino, Grazia ;
Wiechmann, Lisa ;
Osborne, C. Kent ;
Schiff, Rachel .
ENDOCRINE REVIEWS, 2008, 29 (02) :217-233
[2]   The PIK3CA gene is mutated with high frequency in human breast cancers [J].
Bachman, KE ;
Argani, P ;
Samuels, Y ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Konishi, H ;
Karakas, B ;
Blair, BG ;
Lin, C ;
Peters, BA ;
Velculescu, VE ;
Park, BH .
CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775
[3]   Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas [J].
Barbareschi, Mattia ;
Buttitta, Fiamma ;
Felicioni, Lara ;
Cotrupi, Sabrina ;
Barassi, Fabio ;
Del Grammastro, Maela ;
Ferro, Antonella ;
Palma, Paolo Dalla ;
Galligioni, Enzo ;
Marchetti, Antonio .
CLINICAL CANCER RESEARCH, 2007, 13 (20) :6064-6069
[4]   H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 [J].
Chakrabarty, A. ;
Rexer, B. N. ;
Wang, S. E. ;
Cook, R. S. ;
Engelman, J. A. ;
Arteaga, C. L. .
ONCOGENE, 2010, 29 (37) :5193-5203
[5]   CORRELATIONS BETWEEN ESTROGEN-RECEPTOR, PROGESTERONE-RECEPTOR, AND PATIENT CHARACTERISTICS IN HUMAN-BREAST CANCER [J].
CLARK, GM ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (10) :1102-1109
[6]   Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer [J].
Ellis, Matthew J. ;
Lin, Li ;
Crowder, Robert ;
Tao, Yu ;
Hoog, Jeremy ;
Snider, Jacqueline ;
Davies, Sherri ;
DeSchryver, Katherine ;
Evans, Dean B. ;
Steinseifer, Jutta ;
Bandaru, Raj ;
Liu, WeiHua ;
Gardner, Humphrey ;
Semiglazov, Vladimir ;
Watson, Mark ;
Hunt, Kelly ;
Olson, John ;
Baselga, Jose .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (02) :379-390
[7]   Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer [J].
Fu, Xiaoyong ;
Osborne, C. Kent ;
Schiff, Rachel .
BREAST, 2013, 22 :S12-S18
[8]   The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro [J].
Gee, JMW ;
Harper, ME ;
Hutcheson, IR ;
Madden, TA ;
Barrow, D ;
Knowlden, JM ;
McClelland, RA ;
Jordan, N ;
Wakeling, AE ;
Nicholson, RI .
ENDOCRINOLOGY, 2003, 144 (11) :5105-5117
[9]   Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of LetrozoleLapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer [J].
Guarneri, Valentina ;
Generali, Daniele Giulio ;
Frassoldati, Antonio ;
Artioli, Fabrizio ;
Boni, Corrado ;
Cavanna, Luigi ;
Tagliafico, Enrico ;
Maiorana, Antonino ;
Bottini, Alberto ;
Cagossi, Katia ;
Bisagni, Giancarlo ;
Piacentini, Federico ;
Ficarra, Guido ;
Bettelli, Stefania ;
Roncaglia, Enrica ;
Nuzzo, Simona ;
Swaby, Ramona ;
Ellis, Catherine ;
Holford, Clare ;
Conte, PierFranco .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1050-+
[10]   Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase [J].
Gutierrez, MC ;
Detre, S ;
Johnston, S ;
Mohsin, SK ;
Shou, JN ;
Allred, DC ;
Schiff, R ;
Osborne, CK ;
Dowsett, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2469-2476